Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Total Valuation
KalVista Pharmaceuticals has a market cap or net worth of $673.65M. The enterprise value is $322.51M.
Market Cap$673.65M
Enterprise Value$322.51M
Share Statistics
KalVista Pharmaceuticals has 49,715,637 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,715,637
Owned by Insiders11.79%
Owned by Institutions0.22%
Financial Efficiency
KalVista Pharmaceuticals’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -61.55%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-61.55%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee0.00
Profits Per Employee-844.29K
Employee Count150
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of KalVista Pharmaceuticals is -3.30. KalVista Pharmaceuticals’s PEG ratio is -0.12.
PE Ratio-3.30
PS Ratio0.00
PB Ratio2.02
Price to Fair Value2.02
Price to FCF-4.66
Price to Operating Cash Flow-4.68
PEG Ratio-0.12
Income Statement
In the last 12 months, KalVista Pharmaceuticals had revenue of 0.00 and earned -126.64M in profits. Earnings per share was -3.44.
Revenue0.00
Gross Profit-86.17M
Operating Income-140.44M
Pretax Income-135.10M
Net Income-126.64M
EBITDA-134.28M
Earnings Per Share (EPS)-3.44
Cash Flow
In the last 12 months, operating cash flow was -127.65M and capital expenditures -766.00K, giving a free cash flow of -128.41M billion.
Operating Cash Flow-127.65M
Free Cash Flow-128.41M
Free Cash Flow per Share-2.58
Dividends & Yields
KalVista Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change7.91%
50-Day Moving Average11.93
200-Day Moving Average11.07
Relative Strength Index (RSI)59.42
Average Volume (3m)652.08K
Important Dates
KalVista Pharmaceuticals upcoming earnings date is Jul 3, 2025, TBA Not Confirmed.
Last Earnings DateMar 12, 2025
Next Earnings DateJul 3, 2025
Ex-Dividend Date―
Financial Position
KalVista Pharmaceuticals as a current ratio of 9.90, with Debt / Equity ratio of 3.98%
Current Ratio9.90
Quick Ratio9.90
Debt to Market Cap0.00
Net Debt to EBITDA0.18
Interest Coverage Ratio0.00
Taxes
In the past 12 months, KalVista Pharmaceuticals has paid -8.45M in taxes.
Income Tax-8.45M
Effective Tax Rate0.06
Enterprise Valuation
KalVista Pharmaceuticals EV to EBITDA ratio is -2.93, with an EV/FCF ratio of -4.38.
EV to Sales0.00
EV to EBITDA-2.93
EV to Free Cash Flow-4.38
EV to Operating Cash Flow-4.40
Balance Sheet
KalVista Pharmaceuticals has $253.20M in cash and marketable securities with $5.78M in debt, giving a net cash position of -$247.42M billion.
Cash & Marketable Securities$253.20M
Total Debt$5.78M
Net Cash-$247.42M
Net Cash Per Share-$4.98
Tangible Book Value Per Share$5.62
Margins
Gross margin is 63.27%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin63.27%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for KalVista Pharmaceuticals is $27.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$27.38
Price Target Upside109.01% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast-18.75%